SEARCH

SEARCH BY CITATION

References

  • 1
    Van der Woude FJ, Lobatto S, Permin Het al Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; i:425 9.
  • 2
    Niles JL, McCluskey RT, Ahmad MF, Arnaout MA. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 1989; 74:1888 93.
  • 3
    Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiolical potential. Kidney Int 1994; 46:1 15.
  • 4
    Falk RJ & Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318:1651 7.
  • 5
    Charles LA, Falk RJ, Jennette JC. Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. Clin Immunol Immunopathol 1989; 53:243 53.
  • 6
    Kallenberg CGM, Mulder AHL, Cohen Tervaert JW. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am J Med 1992; 93:675 82.
  • 7
    Saxon A, Shanahan F, Landers CJet al A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86:202 10.
  • 8
    Rump JA, Schölmerich J, Gross Vet al A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiol 1990; 181:406 13.
  • 9
    Duerr RH, Targan SR, Landers CJet al Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterol 1991; 100:1385 91.
  • 10
    Mulder AHL, Horst G, Haagsma EBet al Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatol 1993; 17:411 7.
  • 11
    Roozendaal C, Van Milligen de Wit AWM, Haagsma EBet al Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med 1998; 105:393 9.
  • 12
    Lassoued S, Sixou L, Oksman Fet al Antineutrophil cytoplasmic antibodies and antibodies to myeloperoxidase in rheumatoid arthritis. Arthritis Rheum 1991; 34:1069 70.
  • 13
    Mulder AHL, Horst G, Van Leeuwen MAet al Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: characterization and clinical correlates. Arthritis Rheum 1993; 36:1054 60.
  • 14
    Schnabel A, Csernok E, Isenberg DAet al Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus: prevalence, specificities, and clinical significance. Arthritis Rheum 1995; 38:633 7.
  • 15
    Spronk PE, Bootsma H, Horst Get al Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996; 35:625 31.
  • 16
    Freeman HJ. Inflammatory bowel disease with cytoplasmic-staining antineutrophil cytoplasmic antibody and extensive colitis. Can J Gastroenterol 1998; 12:279 82.
  • 17
    Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterol 1998; 115:182 205.
  • 18
    Folwaczny C, Noehl N, Tschop Ket al Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterol 1997; 113:101 6.
  • 19
    Geng X, Biancone L, Dai HHet al Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterol 1998; 114:912 22.
  • 20
    Stevens TRJ, Harley SL, Groomet al Anti-endothelial cell antibodies in inflammatory bowel disease. Dig Dis Sci 1993; 38:426 32.
  • 21
    Klein R, Eisenburg J, Weber Pet al Significance and specificity of antibodies to neutrophils detected by Western blotting for the serological diagnosis of primary sclerosing cholangitis. Hepatol 1991; 14:1147 52.
  • 22
    Duerr RH, Targan SR, Landers CJet al Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterol 1991; 100:1590 6.
  • 23
    Lo SK, Fleming KA, Chapman RWG. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut 1992; 33:1370 5.
  • 24
    Bansi DS, Chapman RW, Fleming KA. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8:881 5.
  • 25
    Bansi DS, Bauducci M, Bergqvist Aet al Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Eur J Gastroenterol Hepatol 1997; 9:575 80.
  • 26
    Peen E, Almer S, Bodemar Get al Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 1993; 34:56 62.
  • 27
    Mulder AHL, Broekroelofs J, Horst Get al Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol 1994; 95:490 7.
  • 28
    Stoffel MP, Csernok E, Herzberg Cet al Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996; 104:54 59.
  • 29
    Walmsley RS, Zhao MH, Hamilton MLet al Anti-neutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut 1997; 40:105 9.
  • 30
    Halbwachs-Mecarelli L, Nusbaum P, Noël LHet al Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1992; 90:79 84.
  • 31
    Mayet WJ, Hermann E, Finsterwalder Jet al Antibodies to cathepsin G in Crohn's disease. Eur J Clin Invest 1992; 22:427 33.
  • 32
    Kossa K, Coulthart A, Ives CTet al Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7:783 9.
  • 33
    Schmitt WH, Csernok E, Flesch BKet al Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA). Adv Exp Med Biol 1993; 336:267 72.
  • 34
    Nassberger L, Ljungh A, Schumacher G, Kollberg B. β-Glucoronidase antibodies in ulcerative colitis. Lancet 1992; 340:734 5.
  • 35
    Kaneko K, Suzuki Y, Yamashiro Y, Yabuta K. Is p-ANCA in ulcerative colitis directed against β-glucuronidase? Lancet 1993; 341:320.
  • 36
    Roozendaal C, Zhao MH, Horst Get al Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel diseases. Clin Exp Immunol 1998; 112:10 6.
  • 37
    Orth T, Kellner R, Diekmann Oet al Identification and characterization of autoantibodies against catalase and α-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol 1998; 112:507 15.
  • 38
    Billing P, Tahir S, Calfin Bet al Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995; 147:979 87.
  • 39
    Vidrich A, Lee J, James Eet al Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995; 15:293 9.
  • 40
    Eggena M, Targan SR, Iwanczyk Let al Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J Immunol 1996; 156:4005 11.
  • 41
    Eggena MP, Targan SR, Vidrich Aet al Histone H1: the UC-specific pANCA target antigen [abstract]. FASEB J 1996; 10:A1079.
  • 42
    Cohavy O, Eggena MP, Parseghian Met al Histone H1, a candidate pANCA antigen in ulcerative colitis [abstract]. Gastroenterol 1997; 112:A951.
  • 43
    Mizoguchi E, Mizoguchi A, Chiba Cet al Antineutrophil cytoplasmic antibodies in T-cell receptor α-deficient mice with chronic enterocolitis. Gastroenterol 1997; 113:1828 35.
  • 44
    Sobajima J, Ozaki S, Osakada Fet al Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Clin Exp Immunol 1997; 107:135 40.
  • 45
    Terjung B, Herzog V, Worman HJet al Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatol 1998; 28:332 40.
  • 46
    Stoffel MP, Csernok E, Gross WL. Target antigen for anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease. Scand J Gastroenterol 1996; 31:943 4.
  • 47
    Schultz H, Csernok E, Johnston TWet al Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA. J Immunol Methods 1997; 205:127 33.
  • 48
    Sobajima J, Ozaki S, Uesugi Het al Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol 1998; 111:402 7.
  • 49
    Jones SJ, Zhao MH, Elliott JD, Lockwood CM. The antigenicity of bactericidal/permeability-increasing protein (BPI) is threatened by serine proteases [abstract]. Clin Exp Immunol 1995; 101 (Suppl. 1):36.
  • 50
    Cohen Tervaert JW. The value of serial ANCA testing during follow-up studies in patients with ANCA-associated vasculitides: a review. J Nephrol 1996; 9:232 40.
  • 51
    Shanahan F. Neutrophil autoantibodies in inflammatory bowel disease: are they important? Gastroenterol 1994; 107:586 9.
  • 52
    Quinton JF, Sendid B, Reumaux Det al Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788 91.
  • 53
    Targan SR, Landers CJ, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterol 1995; 108:1159 66.
  • 54
    Coremans IEM, Hagen EC, Daha MRet al Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum 1992; 35:1466 75.
  • 55
    Uesugi H, Ozaki S, Sobajima Jet al Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol 1998; 25:703 9.
  • 56
    Sobajima J, Ozaki S, Okazaki Tet al Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 1996; 105:120 4.
  • 57
    Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71:431 6.
  • 58
    Reumaux D, Colombel JF, Duclos Bet al Antineutrophil cytoplasmic auto-antibodies in sera from patients with ucerative colitis after proctocolectomy with ileo-anal anastomosis. Adv Exp Med Biol 1993; 336:523 5.
  • 59
    Patel RT, Stokes R, Birch Det al Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Br J Surg 1994; 81:724 6.
  • 60
    Yang P, Oresland T, Jarnerot Get al Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Scand J Gastroenterol 1996; 31:594 8.
  • 61
    Aitola P, Miettinen A, Mattila M, Soppi E. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J Clin Pathol 1995; 48:645 7.
  • 62
    Vecchi M, Gionchetti P, Bianchi MBet al p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994; 344:886 7.
  • 63
    Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90:740 7.
  • 64
    Esteve M, Mallolas J, Klaassen Jet al Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis. Gut 1996; 38:894 8.
  • 65
    Brett PM, Yasuda N, Yiannakou JYet al Genetic and immunological markers in pouchitis. Eur J Gastroenterol Hepatol 1996; 8:951 5.
  • 66
    Subramani K, Harpaz N, Bilotta Jet al Refractory pouchitis: does it reflect underlying Crohn's disease? Gut 1993; 34:1539 42.
  • 67
    Aisenberg J, Wagreich J, Shim Jet al Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis: a case-control study. Dig Dis Sci 1995; 40:1866 72.
  • 68
    Vasiliauskas EA, Plevy SE, Landers CJet al Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterol 1996; 110:1810 9.
  • 69
    Jamar-Leclerc N, Reumaux D, Duthilleul P, Colombel JF. Do pANCA define a clinical subgroup in patients with Crohn's disease? Gastroenterol 1997; 112:316 7.
  • 70
    Oudkerk Pool M, Ellerbroek PM, Ridwan BUet al Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993; 34:46 50.
  • 71
    Schumacher G, Kollberg B, Sandstedt Bet al Circulating granulocyte antibodies in first attacks of colitis. Scand J Gastroenterol 1995; 30:157 63.
  • 72
    Kerr GS, Fleisher TA, Hallahan CWet al Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36:365 71.
  • 73
    Cohen Tervaert JW, Van der Woude FJ, Fauci ASet al Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Int Med 1989; 149:2461 5.
  • 74
    Cohen Tervaert JW, Huitema MG, Hene RJet al Prevention of relapses of Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336:709 11.
  • 75
    Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autoimmun 1997; 10:175 80.
  • 76
    Roozendaal C, Pogány K, Hummel EJet al Titers of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. Submitted for publication.
  • 77
    Roozendaal C, Pogány K, Horst Get al Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases? Submitted for publication.
  • 78
    Shanahan F, Duerr RH, Rotter JIet al Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterol 1992; 103:456 61.
  • 79
    Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterol 1994; 107:532 6.
  • 80
    Reumaux D, Delecourt L, Colombel JFet al Anti-neutrophil cytoplasmic autoantibodies in relatives of patients with ulcerative colitis. Gastroenterol 1992; 103:1706.
  • 81
    Lee JCW, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterol 1995; 108:428 33.
  • 82
    Papo M, Quer CJ, Pastor RMet al Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease. Am J Gastroenterol 1996; 91:1512 5.
  • 83
    Bansi DS, Lo SK, Chapman RW, Fleming KA. Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8:111 6.
  • 84
    Yang H, Rotter JI, Toyoda Het al Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92:1080 4.
  • 85
    Mehal WZ, Lo SK, Chapman RW, Fleming KA. The immunogenetic basis for anti-neutrophil cytoplasmic antibody production in primary sclerosing cholangitis and ulcerative colitis. J Hepatol 1994; 21:910 1.
  • 86
    Perri F, Annese V, Piepoli Aet al HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. Ital J Gastroenterol Hepatol 1998; 30:56 61.
  • 87
    Satsangi J, Landers CJ, Welsh KIet al The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998; 4:18 26.
  • 88
    Yang H, Vora DK, Targan SRet al Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterol 1995; 109:440 8.
  • 89
    Roussomoustakaki M, Satsangi J, Welsh Ket al Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterol 1997; 112:1845 53.
  • 90
    Falk RJ, Terrel RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115 9.
  • 91
    Mulder AHL, Heeringa P, Brouwer Eet al Activation of granulocytes by anti-neutrophil cytoplasmic antibodies: a Fc RII-dependent process. Clin Exp Immunol 1994; 98:270 8.
  • 92
    Van de Wiel BA, Dolman KM, Van der Meer-Gerritsen CH. Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992; 90:409 14.
  • 93
    Griffin SV & Lockwood CM. Anti-myeloperoxidase (MPO) antibodies interfere with the inhibition of MPO by caeruloplasmin [abstract]. The Immunologist 1997; 5 (Suppl. 1):94.
  • 94
    Heeringa P, Brouwer E, Cohen Tervaert JWet al Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int 1998; 53:253 63.
  • 95
    Gionchetti P, Vecchi M, Rizzello Fet al Lack of effect of antineutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils. Gut 1997; 40:102 4.
  • 96
    Peen E, Sundqvist T, Skogh T. Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium. Clin Exp Immunol 1996; 103:403 7.
  • 97
    Targan SR, Landers CJ, King NWet al Ulcerative colitis-linked antineutrophil cytoplasmic antibody in the cotton-top tamarin model of colitis. Gastroenterol 1992; 102:1493 8.
  • 98
    Magnuson JS, Henry JF, Yip TT, Hutchens TW. Structural homology of human, bovine, and porcine milk lactoferrins: evidence for shared antigenic determinants. Pediatr Res 1990; 28:176 81.
  • 99
    Aguas AP, Esaguy N, Sunkel CE, Silva MT. Cross-reactivity and sequence homology between the 65-kilodalton mycobacterial heat shock protein and human lactoferrin, transferrin, and DRβ subsets of major histocompatibility complex class II molecules. Infect Immun 1990; 58:1461 70.
  • 100
    Stevens TRJ, Winrow VR, Blake DR, Rampton DS. Circulating antibodies to heat-shock protein 60 in Crohn's disease and ulcerative colitis. Clin Exp Immunol 1992; 90:271 4.
  • 101
    Spahn TW, Heimann H, Duchmann Ret al Cellular and humoral immunity to the 60-kD heat shock protein in inflammatory bowel disease. Digestion 1997; 58:469 75.
  • 102
    Peen E, Eneström S, Skogh T. Distribution of lactoferrin and 60/65 kDa heat shock protein in normal and inflamed human intestine and liver. Gut 1996; 38:135 40.
  • 103
    Cohavy O, Tayebali AB, Phu PKet al Identification of candidate bacterial pathogens in ulcerative colitis using a disease-specific marker antibody [abstract]. Gastroenterol 1998; 114:G3906.
  • 104
    Kühn R, Löhler J, Rennick Det al Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263 74.
  • 105
    Seibold F, Brandwein S, Simpson Set al pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998; 18:153 60.
  • 106
    Yang P, Danielsson D, Järnerot G. Escherichia coli and Proteus mirabilis inhibit the perinuclear but not the ciculating antineutrophil cytoplasmic antibody reaction. Scand J Gastroenterol 1998; 33:529 34.